MeiraGTx Holdings plc, a clinical-stage genetic medicines company, announced significant progress in its regulatory efforts during the second quarter of 2025. The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for MeiraGTx's AAV-GAD, aimed at treating Parkinson's disease. This designation is an important step towards expedited development and approval. In addition, MeiraGTx, in collaboration with Hologen, has made strides in their joint venture, Hologen Neuro AI Ltd. The collaboration involves a significant financial backing, with MeiraGTx receiving $23 million out of a $200 million cash consideration post-FDI clearance, and further committed funding of up to $230 million from Hologen. This joint venture aims to advance the development and commercialization of the AAV-GAD program and other CNS therapies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。